Professional Documents
Culture Documents
Flaviviridae, ARN
Aedes aegypti
single chain +
Serotypes:
DEN-1, DEN-2,
DEN-3, DEN-4
At present it is a problem in several countries of Latin America because its
incidence has increased in the last decades. It has caused about 1181 deaths,
only in America.
Materials and methods
Obtaining of strains West pac 74
(DEN-1), S16803, (DEN-2), CH53489
(DEN-3), TVP360 (DEN-4)
Beckman
Optima
Max-XP
Incubation for
Virus inactivation with formalin
approximately 15 days
Evaluation of
immunogenicity
Blaney JE Jr, Sathe NS, Hanson CT, Firestone CY, Murphy BR, Whitehead SS, 2007. Vaccine
candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes
of rDEN4 and rDEN4 DEN1. Virol J 4: 23
Fernandez S, Cisney ED, Tikhonov AP, Schweitzer B, Putnak RJ, Simmons M, Ulrich RG, 2011.
Antibody recognition of the dengue virus proteome and implications for development of
vaccines. Clin Vaccine Immunol 18: 523 532
Simmons M, Burgess T, Lynch J, Putnak R, 2010. Protection against dengue virus by non-
replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
Virology 396: 280288.
Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ,
Endy TP, 2006. Protection of rhesus monkeys against dengue virus challenge after
tetravalent live attenuated dengue virus vaccination. J Infect Dis 193: 16581665.
Stefan Fernandez, Stephen J. Thomas, Rafael De La Barrera, Rawiwan Im-erbsin, Richard G.
Jarman, Benot Baras, Jean-Franois Toussaint, Sally Mossman, Bruce L. Innis, Alexander
Schmidt, Marie-Pierre Malice, Pascale Festraets, Lucile Warter, J. Robert Putnak, and
Kenneth H. Eckels*, 2015. An Adjuvanted, Tetravalent Dengue Virus-Purified Inactivated
Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against
Dengue Challenge in Rhesus Macaques